score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4538	130.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				NRAS p.Q61R (Missense)	1.0	MEL-IPI_Pat160	MEL-IPI_Pat160-Tumor-SM-5VWK3	MEL-IPI_Pat160-Normal-SM-5VWIK
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 4	version 2	0.245						Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	"In a cohort of 34 non-small cell lung cancer patients with pembrolizumab, the presence of a smoking signature (""transversion-high"" tumors) was associated with a higher overall response rate (56% in transversion-high tumors, vs. 17% in ""transversion-low"" [never-smoker] tumors), a higher rate of DCB (77% vs. 22%), and a longer PFS."	Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8.	https://doi.org/10.1126/science.aaa1348													0				COSMIC Signature (version 2) 4 (24%)		MEL-IPI_Pat160		
Investigate Actionability			Clinical evidence	Copy Number	ESR1	Deletion				0.0	0.0																Investigate Actionability	0.0	Ampifications of ESR1 was significantly associated with poor disease-free survival and overall survival in a study of 99 patients with ER-positive breast cancer tumors.	Nielsen KV, Ejlertsen B, Muller S, et al. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(2):345-55.	https://doi.org/10.1007/s10549-010-0984-y	0				ESR1 Deletion		MEL-IPI_Pat160	MEL-IPI_Pat160-Tumor-SM-5VWK3	
Biologically Relevant				Copy Number	ROS1	Deletion				0.0	0.0																					0				ROS1 Deletion		MEL-IPI_Pat160	MEL-IPI_Pat160-Tumor-SM-5VWK3	
Biologically Relevant				Copy Number	LIMK2	Deletion				0.0	0.0																					0				LIMK2 Deletion		MEL-IPI_Pat160	MEL-IPI_Pat160-Tumor-SM-5VWK3	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAA58del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAA58del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat160		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.256																									0				COSMIC Signature (version 2) 1 (26%)		MEL-IPI_Pat160		
